{"id":60565,"date":"2024-02-28T06:55:40","date_gmt":"2024-02-28T06:55:40","guid":{"rendered":"https:\/\/medsname.com\/rosuline\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"rosuline","status":"publish","type":"product","link":"https:\/\/medsbase.com\/da\/rosuline\/","title":{"rendered":"Rosuline"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin:0 0 8px 0;font-size:16px;font-weight:700;\">&#9889; Quick Answer &mdash; What is Rosuline?<\/h3>\n<p style=\"margin:0;\"><strong>Rosuline<\/strong> er en <strong>5 \/ 10 mg rosuvastatin tablet<\/strong> from Torrent Pharma &mdash; a high-intensity HMG-CoA reductase inhibitor (statin), hydrophilic. Statins reduce cardiovascular events by <strong>20-30% pr mmol\/L LDL-kolesterolreduktion<\/strong> across primary prevention, secondary prevention, diabetes, and post-stroke populations. Rosuvastatin was introduced by AstraZeneca in 2003 as <strong>Crestor<\/strong>. Hydrophilic statin; primarily excreted unchanged in faeces (10% renal, 90% biliary); minimal CYP metabolism (mostly CYP2C9 modestly). Dose range 5-40 mg once daily; 20-40 mg are high-intensity. Potency: rosuvastatin 20 mg reduces LDL-C by 52%; 40 mg by 55% &mdash; the most potent statin per mg. Typical dose: once daily, evening (for short-half-life statins) or any time for rosuvastatin (half-life long enough that timing does not matter). Main side effects: muscle symptoms (0.1-1% with confirmed CK elevation; up to 10% nocebo muscle aches), mild transaminase elevation (3%), new-onset diabetes in at-risk patients (~0.2 per 100 patient-years). Absolutely contraindicated in pregnancy, active liver disease, rhabdomyolysis history.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>Hvad du f\u00e5r med MedsBase:<\/strong> WHO-GMP certificeret producent \u00b7 Diskret emballage \u00b7 Verdensomsp\u00e6ndende forsendelse \u00b7 1.400+ verificerede <a href=\"https:\/\/medsbase.com\/da\/reviews\/\">kundeanmeldelser<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Hver ordre er d\u00e6kket af vores <a href=\"https:\/\/medsbase.com\/da\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> \u2014 hvis din pakke ikke ankommer inden for 20 hverdage, sender vi en erstatning.<\/p>\n<h3>Hvorfor bestille fra MedsBase<\/h3>\n<p>Vores generiske medicin kommer fra WHO-GMP certificerede producenter og sendes verdensomsp\u00e6ndende i diskret, neutral emballage \u2014 ingen medicinnavn p\u00e5 pakkens ydre. Kortbetalinger h\u00e5ndteres af en reguleret processor (kontoudtogsbeskrivelser inkluderer en reguleret betalingsprocessor \u2014 aldrig \u201cMedsBase\u201d eller medicinnavn). Crypto og SEPA bankoverf\u00f8rsel accepteres ogs\u00e5. Hver ordre er d\u00e6kket af vores Reshipment Assurance Policy.<\/p>\n<h2 class=\"wp-block-heading\">What Is Rosuline?<\/h2>\n<p>Rosuline is an oral 5 \/ 10 mg rosuvastatin tablet from Torrent Pharma, supplied in 30-180 tablets. Rosuvastatin was introduced by AstraZeneca in 2003 as <strong>Crestor<\/strong>. Hydrophilic statin; primarily excreted unchanged in faeces (10% renal, 90% biliary); minimal CYP metabolism (mostly CYP2C9 modestly). Dose range 5-40 mg once daily; 20-40 mg are high-intensity.<\/p>\n<h2 class=\"wp-block-heading\">How Rosuvastatin Works<\/h2>\n<p>Rosuvastatin inhibits <strong>HMG-CoA-reduktase<\/strong>, det hastighedsbegr\u00e6nsende enzym i den hepatiske kolesterolsyntese. Downstream:<\/p>\n<ul>\n<li><strong>Reduceret intracellul\u00e6rt kolesterol i hepatocytter<\/strong> \u2014 udl\u00f8ser sterol-regulatorisk element-bindende protein (SREBP) aktivering og opregulering af LDL-receptorudtryk p\u00e5 hepatocytternes overflade<\/li>\n<li><strong>For\u00f8get clearance af cirkulerende LDL-C<\/strong> \u2014 den prim\u00e6re LDL-s\u00e6nkende mekanisme<\/li>\n<li><strong>Beskeden triglyceridreduktion<\/strong> (10-20%) og beskeden HDL-stigning (5-10%)<\/li>\n<li><strong>Pleiotrope effekter<\/strong> ud over LDL-s\u00e6nkning \u2014 reduceret vaskul\u00e6r inflammation (hs-CRP fald), forbedret endotelfunktion, plaque-stabilisering, reduceret plateletreaktivitet. Omfanget af den kliniske fordel p\u00e5 tv\u00e6rs af fors\u00f8g overstiger, hvad der kan forklares alene ved LDL-C-\u00e6ndring.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Rosuline Dosage<\/h2>\n<p><strong>Prim\u00e6r forebyggelse (ingen tidligere hjerte-kar-h\u00e6ndelse):<\/strong> start 5-10 mg once daily; titrate to target based on 10-year ASCVD risk. For diabetics or ASCVD risk &gt;7.5%, moderate-intensity (10-20 mg) is typical.<\/p>\n<p><strong>Sekund\u00e6r forebyggelse (tidligere hjerteanfald, slagtilf\u00e6lde, PAD eller diabetisk hjerte-kar-sygdom):<\/strong> high-intensity therapy &mdash; 20-40 mg once daily. Target LDL-C &lt;1.8 mmol\/L (&lt;70 mg\/dL) per 2019 ESC and &lt;1.4 mmol\/L (&lt;55 mg\/dL) for very-high-risk ASCVD per 2021 ESC update.<\/p>\n<p><strong>Familial hyperkolesterol\u00e6mi:<\/strong> maximum-tolerated statin (usually 40 mg) often combined with ezetimibe 10 mg and\/or PCSK9 inhibitor (alirocumab\/evolocumab\/inclisiran) to achieve guideline targets.<\/p>\n<p><strong>Administration:<\/strong> once daily with or without food. Any time of day &mdash; 19-hour half-life means timing does not meaningfully change efficacy.<\/p>\n<p><strong>Overv\u00e5gning:<\/strong><\/p>\n<ul>\n<li><strong>Baseline:<\/strong> fuldt lipidpanel, levertal (ALT), kreatinkinase (CK), HbA1c eller fastende blodsukker, kreatinin, thyreoideastimulerende hormon (TSH) hvis ikke nyligt kontrolleret.<\/li>\n<li><strong>4-12 uger:<\/strong> repeat lipids to assess response. Expect rosuvastatin 20 mg reduces LDL-C by 52%; 40 mg by 55% &mdash; the most potent statin per mg. Dose-escalate if target not met.<\/li>\n<li><strong>\u00c5rligt:<\/strong> lipider, levertal (medmindre symptomatisk). CK kun ved muskelklager, ikke rutinem\u00e6ssigt.<\/li>\n<li><strong>Stop og unders\u00f8g:<\/strong> CK &gt;10\u00d7 ULN, ALT &gt;3\u00d7 ULN og stigende, vedvarende uforklarlig muskelsmerte med CK &gt;5\u00d7 ULN, rabdomyolyse (m\u00f8rk urin, markant sv\u00e6kkelse).<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Evidence for Rosuvastatin<\/h2>\n<p><strong>JUPITER (2008)<\/strong> &mdash; rosuvastatin 20 mg in 17,802 patients with normal LDL but elevated hs-CRP reduced CV events by 44%; extended statin indications to &#8220;inflammation-driven&#8221; risk. <strong>ASTEROID (2006)<\/strong> &mdash; 40 mg for 24 months produced measurable coronary plaque regression on IVUS. <strong>SATURN (2011)<\/strong> &mdash; rosuvastatin 40 mg vs atorvastatin 80 mg; rosuvastatin slightly greater LDL reduction but no meaningful regression advantage. <strong>HOPE-3 (2016)<\/strong> &mdash; rosuvastatin 10 mg primary prevention in intermediate-risk patients reduced CV events by 24%.<\/p>\n<h2 class=\"wp-block-heading\">Godkendte og evidensbaserede anvendelser<\/h2>\n<ul>\n<li>Primary and secondary prevention of cardiovascular disease<\/li>\n<li>Inflammation-driven risk with elevated hs-CRP (JUPITER)<\/li>\n<li>Patients who are CYP3A4-interaction-prone (simpler pharmacology than atorvastatin)<\/li>\n<li>Familial hyperkolesterol\u00e6mi<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Praktiske overvejelser<\/h2>\n<p>Fewer CYP3A4 interactions than atorvastatin &mdash; a practical advantage when patients take macrolides, azoles, or certain antiretrovirals. <strong>Dose-capped in Asian patients<\/strong> &mdash; the FDA reduced the Asian starting dose to 5 mg after pharmacokinetic studies showed 2-fold higher plasma levels. <strong>Creatine kinase and LFT monitoring<\/strong> as for all statins.<\/p>\n<h2 class=\"wp-block-heading\">Bivirkninger<\/h2>\n<p><strong>Almindelige (&gt;1%):<\/strong><\/p>\n<ul>\n<li><strong>Myalgia (muskelsmerter)<\/strong> \u2014 generende hos 5-10% af brugerne; bekr\u00e6ftede statin-associerede muskelsymptomer med CK-stigning hos 0,1-1%. H\u00f8j nocebo-komponent: SAMSON-studiet (2020) viste ingen forskel mellem statin og placebo i dobbeltblindede n-of-1 crossover-fors\u00f8g hos mange \u201cstatin-intolerante\u201d patienter.<\/li>\n<li><strong>Let forh\u00f8jelse af transaminaser<\/strong> \u2014 3% har ALT-stigning under 3\u00d7 ULN; normalt midlertidig og kr\u00e6ver ikke dosis\u00e6ndring.<\/li>\n<li><strong>Nyopst\u00e5et diabetes<\/strong> \u2014 absolut overskud ~0,2 pr. 100 patient\u00e5r, hovedsageligt hos pr\u00e6diabetiske patienter. Kardiovaskul\u00e6r fordel langt overstiger diabetesrisiko.<\/li>\n<li><strong>Hovedpine, dyspepsi, kvalme<\/strong><\/li>\n<li><strong>Anvendelser og indikationer<\/strong> (us\u00e6dvanligt; mekanisme uklar)<\/li>\n<li><strong>S\u00f8vnforstyrrelser, kognitiv t\u00e5ge<\/strong> (rapporteret men ikke konsekvent i RCT\u2019er)<\/li>\n<\/ul>\n<p><strong>Ikke almindelige, men klinisk vigtige:<\/strong><\/p>\n<ul>\n<li><strong>Rabdomyolyse<\/strong> (10\u00d7 ULN.<\/li>\n<li><strong>Immunmedieret nekrotiserende myopati<\/strong> \u2014 sj\u00e6lden vedvarende myopati, der forts\u00e6tter efter statinoph\u00f8r; anti-HMGCR-antistofmedieret. Kr\u00e6ver immunosuppressiv behandling.<\/li>\n<li><strong>Alvorlig transaminitis \/ l\u00e6gemiddelinduceret leverskade<\/strong> \u2014 sj\u00e6lden; stop hvis ALT &gt;3\u00d7 ULN med symptomer eller stigende tendens.<\/li>\n<li><strong>Perifer neuropati<\/strong> (sj\u00e6ldent)<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Kontraindikationer<\/h2>\n<ul>\n<li><strong>Graviditet og amning<\/strong> \u2014 statiner er kontraindiceret; kolesterol er n\u00f8dvendig for fosterets neuroudvikling.<\/li>\n<li><strong>Aktiv leversygdom<\/strong> eller uforklarlig vedvarende ALT &gt;3\u00d7 ULN.<\/li>\n<li><strong>Tidligere rhabdomyolyse eller alvorlig statin-intolerans<\/strong> bekr\u00e6ftet ved dobbeltblind reeksponering.<\/li>\n<li><strong>Samtidig brug af st\u00e6rke CYP3A4-h\u00e6mmere<\/strong> (for rosuvastatin): clarithromycin, itraconazole, ritonavir &mdash; hold statin or switch to rosuvastatin\/pravastatin.<\/li>\n<li>Overf\u00f8lsomhed overfor statinet.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">L\u00e6gemiddelinteraktioner<\/h2>\n<ul>\n<li><strong>CYP2C9 and OATP1B1 transporter interactions<\/strong> &mdash; ciclosporin, gemfibrozil, and some antiretrovirals raise rosuvastatin levels. Dose-cap rosuvastatin at 5 mg with ciclosporin; avoid with gemfibrozil.<\/li>\n<li><strong>Grapefrugtjuice<\/strong> &mdash; minimal interaction with rosuvastatin (hydrophilic; minimal CYP3A4 metabolism).<\/li>\n<li><strong>Fibrater (gemfibrozil, fenofibrat)<\/strong> \u2014 \u00f8get risiko for myopati. Gemfibrozil er den v\u00e6rste; fenofibrat er det foretrukne fibrat til kombination. Reserver kombinationer til specialistbehandling af dyslipid\u00e6mi.<\/li>\n<li><strong>H\u00f8j dosis niacin<\/strong> \u2014 \u00f8get risiko for myopati. Lav dosis niacin (1-2 g) tolereres normalt.<\/li>\n<li><strong>Warfarin<\/strong> \u2014 lille INR-stigning ved statinp\u00e5begyndelse; kontroller INR 1 uge efter start. Ikke en kontraindikation.<\/li>\n<li><strong>Digoxin<\/strong> \u2014 lille stigning i digoxinniveau med atorvastatin (P-glykoprotein); er normalt ikke klinisk signifikant.<\/li>\n<li><strong>Alkohol<\/strong> \u2014 h\u00f8jt forbrug \u00f8ger risikoen for leverskade. Moderat forbrug er acceptabelt.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Opbevaring<\/h2>\n<p>Store Rosuline below 25&deg;C in the original blister pack. Keep out of reach of children.<\/p>\n<h2 id=\"faqs\">Ofte stillede sp\u00f8rgsm\u00e5l<\/h2>\n<h3 class=\"wp-block-heading\">Do I have to take Rosuline at night?<\/h3>\n<p>No &mdash; rosuvastatin has a 19-hour half-life, long enough that the ~24-hour cycle of nocturnal cholesterol synthesis is covered regardless of dose timing. Morning dosing with other medications is fine. The &#8220;take statins at night&#8221; rule comes from short-half-life statins (simvastatin, lovastatin).<\/p>\n<h3 class=\"wp-block-heading\">What if I get muscle aches on Rosuline?<\/h3>\n<p>Almindeligt og sj\u00e6ldent farligt. Kontroller kreatinkinase (CK). Hvis CK er normal, er smertene normalt ikke relateret til statiner \u2014 SAMSON-fors\u00f8get (2020) viste, at de fleste \u201cstatin-intolerante\u201d patienter havde lige store smerter p\u00e5 placebo i dobbeltblind crossover. Muligheder: forts\u00e6t statin med D-vitamintilskud (hvis mangel), pr\u00f8v coenzym Q10 (svagt evidens, men lav risiko), skift statin (rosuvastatin har lavere hyppighed af muskelsymptomer end simvastatin og atorvastatin i nogle fors\u00f8g), neds\u00e6t dosen eller brug alternerende dosering. Stop kun, hvis CK &gt;10\u00d7 ULN, symptomer er invaliderende, eller der er objektiv sv\u00e6kkelse.<\/p>\n<h3 class=\"wp-block-heading\">Will Rosuline give me diabetes?<\/h3>\n<p>Statiner for\u00e5rsager en lille overhyppighed af nyopst\u00e5et diabetes \u2014 cirka 1 ekstra diabetes-tilf\u00e6lde pr. 1.000 personer pr. \u00e5r, mest hos dem, der allerede har h\u00f8j diabetesrisiko (overv\u00e6gtig, pr\u00e6diabetes, familiehistorie). Den samme behandling forhindrer cirka 5-10 hjerte-kar-h\u00e6ndelser pr. 1.000 personer pr. \u00e5r i de samme populationer \u2014 s\u00e5 nettofordelen er st\u00e6rkt positiv. Stop ikke en statin p\u00e5 grund af diabetesrisiko alene.<\/p>\n<h3 class=\"wp-block-heading\">Can I take Rosuline with grapefruit juice?<\/h3>\n<p>Yes &mdash; rosuvastatin has minimal CYP3A4 metabolism, so the grapefruit interaction is minor. Contrast with atorvastatin where regular grapefruit consumption is discouraged.<\/p>\n<h3 class=\"wp-block-heading\">How long will I need to take Rosuline?<\/h3>\n<p>P\u00e5 ubestemt tid i n\u00e6sten alle tilf\u00e6lde. Stop af en statin f\u00e5r LDL-C til at stige igen inden for uger, og kardiovaskul\u00e6r beskyttelse tabes inden for m\u00e5neder. Statiner er livslang forebyggende behandling for atherosclerotisk sygdom, ikke en kortvarig kur.<\/p>\n<h3 class=\"wp-block-heading\">Can I take Rosuline in pregnancy?<\/h3>\n<p>Nej \u2014 statiner er kontraindiceret under graviditet og amning. Kolesterol er n\u00f8dvendig for fosterets neuroudvikling; statiner passerer placentaen. Stop statinen f\u00f8r planlagt graviditet; hvis graviditeten er uplanlagt, stop straks og dr\u00f8ft risici med en specialist. Patienter med famili\u00e6r hyperkolesterol\u00e6mi kan som regel sikkert uds\u00e6tte statinbehandling under graviditet og amning.<\/p>\n<h3 class=\"wp-block-heading\">Where can I buy Rosuline online?<\/h3>\n<p>You can buy Rosuline (rosuvastatin 5 \/ 10 mg, 30-180 tablets) from MedsBase with discreet packaging and worldwide shipping.<\/p>\n<h2 class=\"wp-block-heading\">Relaterede hjerte- og blodtryksmedicin<\/h2>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/da\/aldactone\/\">Aldactone \u2014 Spironolacton (ikke-selektiv MR-antagonist)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/amlopres-at\/\">Amlopres AT \u2014 Amlodipin + Atenolol kombination<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/aten\/\">Aten \u2014 Atenolol (betablokker)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/ecosprin\/\">Ecosprin \u2014 Aspirin 75\/150 mg<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/eptus\/\">Eptus \u2014 Eplerenon 25\/50 mg (selektiv MR-antagonist)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/lotensyl\/\">Lotensyl \u2014 Cilnidipine 10\/20 mg (L+N-type CCB)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/high-blood-pressure-medication\/\"><strong>Se alle h\u00f8jtryksmedicin<\/strong><\/a><\/li>\n<\/ul>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:16px 20px;margin:24px 0;border-radius:4px;\"><strong>\u2695 Medicinsk ansvarsfraskrivelse.<\/strong> Denne side er kun til informationsform\u00e5l og erstatter ikke l\u00e6gefaglig r\u00e5dgivning fra en kvalificeret sundhedsfaglig person. Hypertension, hjerteinsufficiens og arytmier kr\u00e6ver diagnose, overv\u00e5gning og individuel dosering af en l\u00e6ge \u2014 brug altid beta-blokkere under l\u00e6gelig vejledning.<\/div>\n<h3 class=\"wp-block-heading\">Hvorfor bestille fra MedsBase<\/h3>\n<p>Rosuline is supplied through a WHO-GMP certified manufacturer with full COA documentation. We ship worldwide in plain, discreet packaging, and every order is covered by our <a href=\"\/da\/medsbase-re-shipment-assurance-policy\/\">Reshipment Assurance Policy<\/a>. Din betalingsbeskrivelse ved kortbetaling viser den regulerede betalingsprocessor (en reguleret kortbetalingsprocessor), aldrig \u201cMedsBase\u201d eller noget medicinsk produktnavn.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">Relaterede alternativer<\/h3>\n<p>Andre produkter inden for <strong>Kroniske tilstande<\/strong> som kunder ogs\u00e5 ser:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/da\/triohale-inhaler\/\">Triohale Inhaler<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/montair\/\">Montair<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/lomoother\/\">Lomoother<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/unicontin-e\/\">Unicontin-E<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/ventocortil\/\">Ventocortil<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>Rosuline is Torrent Pharma&#8217;s rosuvastatin 5\/10 mg tablets \u2014 the most potent statin per mg. Originally AstraZeneca Crestor (2003). Hydrophilic, predominantly biliary clearance, minimal CYP3A4 metabolism \u2014 making it the preferred statin for patients on macrolides, azoles, or antiretrovirals. JUPITER (2008) extended statin indications to normal-LDL, high-hsCRP populations. HOPE-3 (2016) primary prevention in intermediate risk. Asian patients start at 5 mg (pharmacokinetic dose-cap).<\/p>","protected":false},"featured_media":60566,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3260,3356,3953],"product_tag":[4882,4637],"class_list":{"0":"post-60565","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-heart-blood-pressure","9":"product_cat-high-blood-pressure-medication","10":"product_cat-high-cholesterol-treatments","11":"product_tag-rosuline","12":"product_tag-rosuvastatin","14":"first","15":"instock","16":"shipping-taxable","17":"purchasable","18":"product-type-variable","19":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/product\/60565","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/comments?post=60565"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/media\/60566"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/media?parent=60565"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/product_brand?post=60565"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/product_cat?post=60565"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/product_tag?post=60565"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}